FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058936368> ?p ?o ?g. }

• W2058936368 endingPage "258" @default.
• W2058936368 startingPage "251" @default.
• W2058936368 abstract "Enzastaurin is a selective protein kinase Cβ inhibitor which is shown to have direct antitumor effect as well as suppress glycogen synthase kinase-3β (GSK-3β) phosphorylation (resulting in its activation) in both tumor tissues and peripheral blood mononuclear cells (PBMC). It is currently used in phase II trials for the treatment of colon cancer, refractory glioblastoma and diffuse large B cell lymphoma. In this study, the direct effect of enzastaurin on effector function of human natural killer (NK) cells was investigated. The results obtained showed that enzastaurin suppressed both natural and antibody-dependent cellular cytotoxicity (ADCC) of NK cells against different tumor targets. This inhibition was associated with a specific down-regulation of surface expression of NK cell activating receptor NKG2D and CD16 involved in natural cytotoxicity and ADCC respectively, as well as the inhibition of perforin release. Analysis of signal transduction revealed that enzastaurin activated GSK-3β by inhibition of GSK-3β phosphorylation. Treatment of NK cells with GSK-3β-specific inhibitor TDZD-8 prevented enzastaurin-induced inhibition of NK cell cytotoxicity. Apart from the known antitumor and antiangiogenic effects, these results demonstrate that enzastaurin suppresses NK cell activity and may therefore interfere with NK cell-mediated tumor control in enzastaurin-treated cancer patients." @default.
• W2058936368 created "2016-06-24" @default.
• W2058936368 creator A5006948743 @default.
• W2058936368 creator A5019239135 @default.
• W2058936368 creator A5049194142 @default.
• W2058936368 creator A5052127920 @default.
• W2058936368 creator A5058177040 @default.
• W2058936368 creator A5074740364 @default.
• W2058936368 date "2011-01-01" @default.
• W2058936368 modified "2023-09-27" @default.
• W2058936368 title "The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β" @default.
• W2058936368 cites W1524549767 @default.
• W2058936368 cites W1558018395 @default.
• W2058936368 cites W1559474615 @default.
• W2058936368 cites W1560450744 @default.
• W2058936368 cites W1580579112 @default.
• W2058936368 cites W1584987732 @default.
• W2058936368 cites W1593185873 @default.
• W2058936368 cites W1604829025 @default.
• W2058936368 cites W1758789982 @default.
• W2058936368 cites W1966282104 @default.
• W2058936368 cites W1969950463 @default.
• W2058936368 cites W1970293699 @default.
• W2058936368 cites W1972178991 @default.
• W2058936368 cites W1975046195 @default.
• W2058936368 cites W1981087559 @default.
• W2058936368 cites W1986041760 @default.
• W2058936368 cites W1986290063 @default.
• W2058936368 cites W1989014254 @default.
• W2058936368 cites W1991409470 @default.
• W2058936368 cites W1991895418 @default.
• W2058936368 cites W1992614972 @default.
• W2058936368 cites W1994208977 @default.
• W2058936368 cites W2008338411 @default.
• W2058936368 cites W2008879114 @default.
• W2058936368 cites W2010358055 @default.
• W2058936368 cites W2015210347 @default.
• W2058936368 cites W2022212375 @default.
• W2058936368 cites W2032125984 @default.
• W2058936368 cites W2033617468 @default.
• W2058936368 cites W2034364195 @default.
• W2058936368 cites W2037785147 @default.
• W2058936368 cites W2042763527 @default.
• W2058936368 cites W2048435508 @default.
• W2058936368 cites W2051546748 @default.
• W2058936368 cites W2053073742 @default.
• W2058936368 cites W2056206771 @default.
• W2058936368 cites W2056771287 @default.
• W2058936368 cites W2058138221 @default.
• W2058936368 cites W2059354338 @default.
• W2058936368 cites W2064913654 @default.
• W2058936368 cites W2068609129 @default.
• W2058936368 cites W2081598827 @default.
• W2058936368 cites W2082801302 @default.
• W2058936368 cites W2082804884 @default.
• W2058936368 cites W2083039812 @default.
• W2058936368 cites W2090320233 @default.
• W2058936368 cites W2093954984 @default.
• W2058936368 cites W2097233541 @default.
• W2058936368 cites W2098301543 @default.
• W2058936368 cites W2100125128 @default.
• W2058936368 cites W2107922203 @default.
• W2058936368 cites W2111262648 @default.
• W2058936368 cites W2115962982 @default.
• W2058936368 cites W2116425029 @default.
• W2058936368 cites W2117018068 @default.
• W2058936368 cites W2120601121 @default.
• W2058936368 cites W2123499559 @default.
• W2058936368 cites W2125163646 @default.
• W2058936368 cites W2126372596 @default.
• W2058936368 cites W2135760554 @default.
• W2058936368 cites W2137154569 @default.
• W2058936368 cites W2145172632 @default.
• W2058936368 cites W2148042737 @default.
• W2058936368 cites W2148985681 @default.
• W2058936368 cites W2172187886 @default.
• W2058936368 doi "https://doi.org/10.1016/j.bcp.2010.09.026" @default.
• W2058936368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20934407" @default.
• W2058936368 hasPublicationYear "2011" @default.
• W2058936368 type Work @default.
• W2058936368 sameAs 2058936368 @default.
• W2058936368 citedByCount "8" @default.
• W2058936368 countsByYear W20589363682013 @default.
• W2058936368 countsByYear W20589363682015 @default.
• W2058936368 countsByYear W20589363682016 @default.
• W2058936368 countsByYear W20589363682018 @default.
• W2058936368 countsByYear W20589363682022 @default.
• W2058936368 crossrefType "journal-article" @default.
• W2058936368 hasAuthorship W2058936368A5006948743 @default.
• W2058936368 hasAuthorship W2058936368A5019239135 @default.
• W2058936368 hasAuthorship W2058936368A5049194142 @default.
• W2058936368 hasAuthorship W2058936368A5052127920 @default.
• W2058936368 hasAuthorship W2058936368A5058177040 @default.
• W2058936368 hasAuthorship W2058936368A5074740364 @default.
• W2058936368 hasBestOaLocation W20589363682 @default.
• W2058936368 hasConcept C109316439 @default.
• W2058936368 hasConcept C182996813 @default.
• W2058936368 hasConcept C184235292 @default.

• next